LAEKNA-B(02105): In accordance with the share repurchase authorization, conducting on-market share repurchases and a senior management share acquisition plan.
Kaila Pharmaceuticals-B (02105) announced that, in order to demonstrate confidence in the future business prospects of the company and create value for shareholders, the board of directors approved on July 1, 2026, the repurchase of ordinary shares (shares) of the company on the open market. This approval is based on the general authorization for repurchase of shares approved by shareholders at the annual general meeting held on June 5, 2026, as well as any subsequent repurchase authorization approved by shareholders at future general meetings.
Notice: Laekna-B (02105) announces, in order to demonstrate confidence in the company's business prospects and create value for shareholders, the Board of Directors approved on July 1, 2026, the repurchase of the company's ordinary shares in the public market in accordance with the general authorization for share repurchase approved by shareholders at the annual general meeting held on June 5, 2026, and any subsequent repurchase authorization approved by shareholders at future general meetings (repurchase authorization). At the same time, the Board learned that Dr. Lv Xiangyang, Chairman of the Board of Directors, along with several senior management members of the company, intend to increase their shareholding in the company by purchasing company shares in the public market. The company and senior management will carry out on-market share repurchase and shareholding increase plans in accordance with the company's articles of association, the rules of the Hong Kong Stock Exchange (HKEx), and other applicable laws and regulations. The on-market share repurchase plan will be funded by the company's existing available cash resources. The shares repurchased by the company will subsequently be cancelled. The senior management's shareholding increase plan will be funded by their personal financial resources. These coordinated actions reflect the confidence of the Board and management in the company's business prospects and future development, and will benefit the company and create value for shareholders. The total amount of the company's on-market share repurchase and senior management's shareholding increase plan will not exceed HK$56 million.
Related Articles

HK Stock Market Move | SIMCERE PHARMA(02096) has risen nearly 9% again. Major banks such as UBS have given it a "buy" rating. The company's performance has achieved significant growth.

HK Stock Market Move | Bairong Intelligence (06608) rises over 6%, Hong Hao joins to help the company optimize the capital market's value transmission system, and the AI application layer pricing is expected to receive attention again.

HK Stock Market Move | MOBVISTA (01860) rose more than 10% in midday trading, the network effect and AI infrastructure resonating to construct a growth flywheel.
HK Stock Market Move | SIMCERE PHARMA(02096) has risen nearly 9% again. Major banks such as UBS have given it a "buy" rating. The company's performance has achieved significant growth.

HK Stock Market Move | Bairong Intelligence (06608) rises over 6%, Hong Hao joins to help the company optimize the capital market's value transmission system, and the AI application layer pricing is expected to receive attention again.

HK Stock Market Move | MOBVISTA (01860) rose more than 10% in midday trading, the network effect and AI infrastructure resonating to construct a growth flywheel.

RECOMMEND





